Pre content


Content bottom
Switch off smileys
List  Previous  Next  View thread
Respond     Vote up     Email to a friend     Neighbourhood Watch
Author d gaser     View Profile     Add to favourites     Ignore
Date posted 2018-01-19 17:12
Subject Re: Northwestern Uni Adopts TheraSpher a...   View parent message
Votes for this Posting Voted UP 2 times.
As far as I know is that this university Hospital have been trialling the product and as I understand it they concluded it gives greater life expectancy than the present treatments, and because of that they will use it as a first line medicine ,cost will obviously come into that equation but as it can be done in a day, as a day patient ,that means less visits to the hospital, and it’s less invasive than the present treatments,

If you click on to the above web site I think most of your questions can be answered there ,regarding how many people it could help ,however, as far as I know, this product has not yet received FDA clearance. (see the BTG web site for clarification ,

you will see there it states that the DC Bead® is not currently cleared by the FDA for sale or distribution in the USA ,but it does have clearance in China, EU, Japan, Republic of Korea ,and can be used in the US , under certain rules see .

It might be that this universerty hospital has some thing to do with getting FDA clearance. how ever the fact that this institution has adopted the Y90 transarterial radioembolisation (TARE) with TheraSphere® is a big step forward, as TheraSphere® is also approved for the treatment of hepatic neoplasia in the US , and TheraSphere® it self has all ready been approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant .

The fact that Northweston and it’s hospital have decided to recommend TheraSphere® with Y90 as a first-line transarterial LRT for its patients with HCC means a lot more people will be given it .

The other thing is the American Cancer society talk about the process favourable in their documents, I would suggest that others will now follow suit in due course, and according to the Centre for Disease Control and Protection (CDC) each year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the United States alone.

But let’s say only 25% of those patients where to be treated with our product as a first line treatment, then BTG would be looking at a worldwide block buster product, worth billions of pounds. It’s also worth looking at
Respond     Vote up     Email to a friend     Neighbourhood Watch
Switch off smileys
List  Previous  Next  View thread
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited. You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong. Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.

The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements. Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in. Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.

Discussion Board Terms & Conditions FCA'S FSA Market Abuse Fact Sheet

Bottom Leader Board Area